Compare LAKE & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAKE | IPSC |
|---|---|---|
| Founded | 1982 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.3M | 58.3M |
| IPO Year | 1986 | 2021 |
| Metric | LAKE | IPSC |
|---|---|---|
| Price | $7.96 | $0.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $17.33 | $3.00 |
| AVG Volume (30 Days) | 428.5K | ★ 1.3M |
| Earning Date | 12-09-2025 | 11-13-2025 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $193,456,000.00 | $113,337,000.00 |
| Revenue This Year | $29.73 | $1,590.09 |
| Revenue Next Year | $8.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 27.42 | ★ 4122.69 |
| 52 Week Low | $7.77 | $0.34 |
| 52 Week High | $27.28 | $1.19 |
| Indicator | LAKE | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 18.62 | 85.37 |
| Support Level | $7.77 | $0.54 |
| Resistance Level | $8.44 | $0.95 |
| Average True Range (ATR) | 0.59 | 0.06 |
| MACD | -0.46 | 0.04 |
| Stochastic Oscillator | 2.72 | 95.17 |
Lakeland Industries Inc manufactures and sells safety garments and accessories for the industrial protective clothing market. Its product segments include Disposables, Chemicals, Fire, Gloves, High Visibility, High-Performance Wear, and Wovens. Its customers include integrated oil, chemical/petrochemical, utilities, automobile, steel, glass, construction, smelting, munition plants, janitorial, pharmaceutical, and mortuaries, as well as scientific and medical laboratories. Its geographical segments include the United States, Latin America, Canada, Asia, Mexico, Europe (United Kingdom), and Other Foreign.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.